Why the study?
Does telmisartan prevent epirubicin-induced subclinical myocardial dysfunction, inflammation, and oxidative stress in cancer patients?
Population
49 cardiovascular disease-free patients with cancer at different sites eligible for epirubicin-based…
Comparison
Telmisartan vs Placebo
Design
RCT, randomized to one of two arms, placebo-controlled
Follow-up
12 months
Authors
Loading...
Supports telmisartan with epirubicin to normalize strain rate; extends ARB cardioprotection evidence in anthracycline recipients.
Does telmisartan prevent epirubicin-induced subclinical myocardial dysfunction, inflammation, and oxidative stress in cancer patients?
Telmisartan may prevent long-term epirubicin-induced subclinical myocardial dysfunction and reduce associated inflammation and oxidative stress in cancer patients.
Dessì et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: